Q1FY27 Result update
18th Aug 2026

India Glycols Ltd

Demerger unlocking three pure-play leaders.

CMP: INR 1,071

Rating: BUY

Target Price: INR 1,639

Stock Info	
BSE	500201
NSE	INDIAGLYCO
Bloomberg	IGLY:IN
Reuters	IGLY.NS
Sector	Chemicals
Face Value (INR cr)	5
Equity Capital (INR cr)	31
Mkt Cap (INR cr)	7,178
52w H/L (INR)	1,223 / 792
Avg Yearly Volume (in 000')	184.7

Shareholding Pattern % *(As on Jun, 2026)*	
Promoters	59.63
DII	5.21
FII	2.24
Public & Others	32.91

Stock Performance (%)	3m	6m	12m
IGL	6.2	11.5	19.9
NIFTY	2.7	-5.6	-2.4

IGL vs Nifty



Abhishek Jain
Head of Research & Director
abhishek.jain@arihantcapital.com
022-67114871

Balasubramanian A
Senior Research Analyst
bala@arihantcapital.com
022-67114870

India Glycols Ltd reported numbers, Q1FY27 revenue stood at INR 1,130cr (+8.6% YoY/+15.8% QoQ); below our estimates of INR 1,180r, supported by recovery in chemical and ennature biopharma business. Gross Profit stood at INR 433cr (+19.3% YoY/+17.2% QoQ); above our estimates of INR 413cr. Gross margins improved by 342 bps YoY (+47 bps QoQ) to 38.3% in Q1FY27, due to better product mix and pricing. EBITDA stood at INR 170cr (+13.3% YoY/+1.8% QoQ); in-line with our estimates of INR 173cr. EBITDA margin improved by 62 bps YoY (-205 bps QoQ) to 15% in Q1FY27, due to premiumization and cost optimization. PAT stood at INR 97cr (+32.2% YoY/+11.5% QoQ); in-line with our estimates of INR 99cr. PAT margin improved by 153 bps YoY (-33 bps QoQ) to 8.6% in Q1FY27.

Key Highlights

Value unlocking via strategic demerger: The NCLT-approved trifurcation into India Glycols Ltd (specialty chemicals), IGL Spirits Ltd (spirits + biofuels), and Ennature Bio Pharma Ltd (nutraceuticals/APIs) is a major catalyst. This restructuring eliminates the conglomerate discount by creating three pure-play entities, each with distinct operational dynamics, enabling sharper management focus. Post-demerger, each business can pursue its own growth trajectory and unlocking significant shareholder value.

Growth & Margin expansion across diversified businesses: IGL Spirits Ltd is dominant market leader in UP/Uttarakhand with captive ENA production ensuring cost leadership. IMFL revenue grew 26% YoY to 1.4mn cases, with Prestige & Above nearly doubling. Premiumization focus includes new launches in deluxe whisky, semi-premium vodka, and white spirits, with revenue growth expected to outpace volume growth. The Amrut partnership and exclusive Bacardi maturation facilities strengthen the premium portfolio. The management aspired EBITDA of INR 500cr+ in FY27E and INR 1000cr+ over 4-5 years. India Glycols Ltd (Chemicals) is the world's largest supplier of bio-based specialty chemicals and pioneer in bio-based amines and carbon-smart glycols. It has strong partnerships with Dove, L'Oréal, Unilever. The management aspired INR 2,500cr revenue and INR 400cr+ EBITDA in 4-5 years. In Ennature Bio Pharma Ltd, Nicotine business grew 2x QoQ with new capacity at Kashipur. The management is targeting IN 130-150cr EBITDA in 4-5 years.

Financial discipline and clear path to debt-free: Finance costs reduced to INR 25cr (-43.6% YoY) in Q1FY27, due to active debt reduction. The has a clear target to become debt-free from FY28 onwards, which will further boost bottom-line. Capex is expected to be minimal at INR 5-20cr for FY27E, with no large-scale capex planned for at least two years, as the company focuses on modular expansions using existing assets.

Outlook & Valuation: India Glycols is in a transformative and value-accretive phase, driven by an NCLT-approved demerger into three focused pure-play entities, which is expected to unlock shareholder value. The spirits business, with dominant market share in UP/Uttarakhand and captive ENA cost leadership, is aggressively expanding its premium IMFL portfolio (26% YoY growth) through partnerships with Amrut and Bacardi. The spirits business is targeting INR 500cr+ EBITDA for FY27E and a top-alco-bev position. The chemicals business, as the world's largest bio-based specialty chemicals player, is capitalizing on the global sustainability shift with innovations like bio-based amines, targeting INR 2,500cr in revenue and INR 400cr in EBITDA over 4-5 years. Ennature Bio Pharma, with its best-ever quarter and nicotine growth (2x QoQ), targets INR 130-150cr in EBITDA in 4-5 years. We estimate revenue/EBITDA/PAT CAGR of 12%/15.4%/29% over the period of FY26-29E, with EBITDA margin expanding to 16.9% (FY29E). At the CMP of INR 1,071 per share, we maintain our "BUY" rating at a TP of INR 1,639 per share, based on SOTP; an upside of 53%.

Q1FY27 Results

Exhibit 1: Income statement summary

Particular (INR cr)	Q1FY26	Q4FY26	Q1FY27	YoY (%)	QoQ (%)
Revenue	**1,040**	**976**	**1,130**	**8.6%**	**15.8%**
Net Raw Materials	677	607	697	2.9%	14.9%
Gross Profit	**363**	**369**	**433**	**19.3%**	**17.2%**
Gross Margin (%)	**34.9%**	**37.8%**	**38.3%**	**+342 bps**	**+47 bps**
Power & Fuel	92	88	115	26.1%	31.6%
Employee Cost	31	34	38	20.8%	9.7%
Other Expenses	91	81	110	21.7%	36.4%
EBITDA	**150**	**167**	**170**	**13.3%**	**1.8%**
EBITDA Margin (%)	**14.4%**	**17.1%**	**15.0%**	**+62 bps**	**-205 bps**
Depreciation	34	41	42		
Interest expense	45	26	25	-43.6%	-4.7%
Other income	1	1	0		
Share of profits associate & JV	19	13	21		
Profit before tax	**91**	**112**	**123**	**35.7%**	**9.3%**
Taxes	17	26	26		
PAT	**73**	**87**	**97**	**32.2%**	**11.5%**
PAT Margin (%)	**7.0%**	**8.9%**	**8.6%**	**+153 bps**	**-33 bps**
EPS (INR)	**11.8**	**13.0**	**14.4**		

Source: Company Reports, Arihant Capital Research

Exhibit 2: Gross margins improved by 342 bps YoY (+47 bps QoQ) to 38.3% in Q1FY27 due to better product mix and pricing.



Source: Company Reports, Arihant Capital Research

Exhibit 3: EBITDA margin improved by 62 bps YoY (-205 bps QoQ) to 15% in Q1FY27; led by gros margin impact, however partially offset by higher employee and other expenses in-terms of sales.



Source: Company Reports, Arihant Capital Research

Quarterly results and segments

Exhibit 4: In Potable Spirits, IMFL revenue +26% YoY; Prestige & Above nearly doubled; Premiumization focus with new deluxe whisky & semi-premium vodka launches; Amrut partnership for 5 brands in North India; Exclusive Bacardi maturation facility; Dominant UP/Uttarakhand share; Captive ENA ensuring cost leadership. In Chemicals, bio-based amines & carbon-smart glycols launched; strong partnerships with Dove, L'Oréal, Unilever; exports to the Middle East disrupted. In Ennature Biopharma, Thioicolchicoside sales grew 26% QoQ driven by strong order pipeline and improved price realizations. Nicotine business grew 2x QoQ driven by European customer conversions.

Segment Revenue (INR cr)	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26	Q4FY26	Q1FY27	YoY (%)	QoQ (%)
Bio Based Specialities and Performance Chemicals	325	254	300	288	313	301	363	21.1%	20.6%
Potable Sprits	328	284	342	338	345	306	361	5.3%	17.7%
Ennature Biopharma	50	52	51	43	50	63	83	65.0%	31.2%
Bio-Fuel	272	273	348	423	394	305	323	-7.0%	5.9%
Total Segment Revenue	**975**	**863**	**1,040**	**1,092**	**1,102**	**976**	**1,130**	**8.6%**	**15.8%**

Segment Revenue (%)	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26	Q4FY26	Q1FY27	YoY (%)	QoQ (%)
Bio Based Specialities and Performance Chemicals	33.4%	29.5%	28.8%	26.4%	28.4%	30.8%	32.1%		
Potable Sprits	33.7%	32.9%	32.9%	30.9%	31.3%	31.4%	31.9%		
Ennature Biopharma	5.1%	6.0%	4.9%	4.0%	4.6%	6.5%	7.4%		
Bio-Fuel	27.8%	31.7%	33.4%	38.7%	35.8%	31.3%	28.6%		
Total Segment Revenue	**100.0%**	**100.0%**	**100.0%**	**100.0%**	**100.0%**	**100.0%**	**100.0%**		

Source: Company Reports, Arihant Capital Research

Exhibit 5: Bio fuels margin expansion supported by spirits synergy, captive ethanol, operational efficiency. Ennature Biopharma margin expansion supported by Nicotine 2x QoQ, Thioicolchicoside up 26% QoQ, new Kashipur capacity, better pricing. Spirits business margin maintained due to captive ENA cost leadership, Amrut/Bacardi partnerships.

Segment EBIT (INR cr)	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26	Q4FY26	Q1FY27	YoY (%)	QoQ (%)
Bio Based Specialities and Performance Chemicals	28	29	33	31	40	37	31	-3.7%	-14.6%
Potable Sprits	73	78	72	72	72	68	75	3.7%	10.7%
Ennature Biopharma	5	4	1	1	2	3	7	504.2%	140.9%
Bio-Fuel	9	16	23	29	33	30	27	19.2%	-10.5%
Segment EBIT	**114**	**128**	**129**	**134**	**148**	**138**	**141**	**9.2%**	**2.1%**

Segment EBIT Margin (%)	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26	Q4FY26	Q1FY27	YoY (%)	QoQ (%)
Bio Based Specialities and Performance Chemicals	8.5%	11.4%	10.9%	10.9%	12.8%	12.2%	8.6%	-223 bps	-356 bps
Potable Sprits	22.3%	27.6%	21.1%	21.4%	21.0%	22.1%	20.8%	-32 bps	-131 bps
Ennature Biopharma	9.0%	8.3%	2.4%	2.3%	4.1%	4.7%	8.7%	+633 bps	+396 bps
Bio-Fuel	3.3%	5.8%	6.5%	6.9%	8.4%	9.9%	8.4%	+184 bps	-153 bps
Segment EBIT Margin	**11.7%**	**14.8%**	**12.4%**	**12.3%**	**13.4%**	**14.1%**	**12.4%**	**+7 bps**	**-166 bps**

Source: Company Reports, Arihant Capital Research

Exhibit 6: Potable spirits growth 22.9% YoY (+31.3% QoQ) in Q1FY27, while higher excise duty in-terms of sales impacted revenue growth (+5.3% YoY/+17.7% QoQ) in Q1FY27.

Potable Spirits (INR cr)	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26	Q4FY26	Q1FY27	YoY (%)	QoQ (%)
Potable Spirits	1,777	1,609	1,805	1,658	1,793	1,690	2,219	22.9%	31.3%
Less: Excise duty	1,449	1,325	1,463	1,320	1,449	1,384	1,858	27.0%	34.3%
Excise duty as a % of sales	*81.5%*	*82.4%*	*81.0%*	*79.6%*	*80.8%*	*81.9%*	*83.7%*	3.4%	2.3%
Net Potable Spirits	**328**	**284**	**342**	**338**	**345**	**306**	**361**	**5.3%**	**17.7%**

Source: Company Reports, Arihant Capital Research

Exhibit 7: Raw material growth is lower than revenue growth due to due to better product mix and pricing. However, employee cost, power and other expenses increased.

Particular (INR cr)	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26	Q4FY26	Q1FY27	YoY (%)	QoQ (%)
Revenue	**975**	**863**	**1,040**	**1,092**	**1,102**	**976**	**1,130**	**8.6%**	**15.8%**
Raw material costs	622	534	677	686	692	607	697	2.9%	14.9%
Raw material costs as % of sales	*63.8%*	*61.8%*	*65.1%*	*62.8%*	*62.7%*	*62.2%*	*61.7%*		
Employee costs	31	31	31	32	35	34	38	20.8%	9.7%
Employee costs as % of sales	*3.2%*	*3.5%*	*3.0%*	*2.9%*	*3.2%*	*3.5%*	*3.3%*		
Power & Fuel costs	105	75	92	115	106	88	115	26.1%	31.6%
Power & Fuel costs as % of sales	*10.7%*	*8.7%*	*8.8%*	*10.6%*	*9.6%*	*9.0%*	*10.2%*		
Other expenses	94	77	91	101	94	81	110	21.7%	36.4%
Other expenses as % of sales	*9.6%*	*9.0%*	*8.7%*	*9.3%*	*8.5%*	*8.3%*	*9.8%*		

Source: Company Reports, Arihant Capital Research

Q1FY27 Concall Highlights

NCLT Demerger approval

- The NCLT sanctioned the demerger scheme on July 17, 2026; the effective date is pending.
- Post-demerger, the company will trifurcate into three focused entities: India Glycols Ltd (bio-based chemicals, specialty glycols, performance chemicals, gases), IGL Spirits Ltd (portable spirits including IMFL and country liquor, biofuels), and Ennature Bio Pharma Ltd (nutraceuticals, APIs, biopolymers).

IGL Spirits - Potable Spirits

- IMFL revenue grew 26% YoY to 1.4mn cases, with Prestige & Above at 0.5mn cases.
- Non-IMFL (country liquor) revenue was flat at INR 279cr, though volumes grew 6% YoY.
- The company maintains a dominant market share in UP and Uttarakhand in country liquor, with strong brands like Bunty Bubbly.
- Premiumization is the key focus, with new launches planned in deluxe whisky, semi-premium vodka, and white spirits (fastest-growing category).
- Revenue growth is expected to outpace volume growth due to mix improvement.
- The Amrut partnership covers distribution of five brands in North Indian markets, with plans to double volumes and expand eastward.
- A 15-year exclusive maturation partnership with Bacardi reinforces manufacturing credibility.
- Defense canteen approvals for 3-4 brands provide an all-India footprint opportunity.
- Captive high-quality ENA production ensures cost leadership and margin protection.
- The management targets EBITDA of INR 500cr+ for IGL Spirits in FY27E and INR 1,000cr+ over 4-5 years.

IGL Spirits Ltd - Biofuels

- The synergy between biofuels and portable spirits is significant, as the ethanol produced is a key raw material for the spirits business, ensuring consistent quality and cost leadership.
- The company manufactures one of the best qualities of ENA and is one of the largest manufacturers, providing sustainable cost advantages and protecting margins in its operating states.

Q1FY27 Concall Highlights

India Glycols Ltd - Chemicals

- Green solvents (glycols and glycol ethers) volumes grew 6% YoY, value grew 13% YoY in Q1FY27. Gross margins close to 50%.

- Glycols business value surged 83% YoY with strong margin expansion.

- Performance chemicals grew 40% YoY but missed targets due to export disruptions to the Middle East and raw material shortages.

- The company is the world's largest supplier of bio-based specialty chemicals and pioneer in bio-based EO and glycols. It became the first company to manufacture bio-based amines and first to supply carbon-smart ethoxylates and glycols. Strong collaborative partnerships exist with Dove, L'Oréal, and Unilever.

- Crude spike made bio-EO cost-competitive (tailwind), but raw material shortages, collapsed Middle East exports, and freight spikes (5-20x) created headwinds.

- The management aspired to INR 2,500cr revenue with INR 400cr EBITDA in 4-5 years.

Ennature Bio Pharma Ltd

- Thioicolchicoside sales grew 26% QoQ in Q1FY27. Nicotine business sales grew 2x QoQ driven by European customer conversions, with new crude processing capacity added at Kashipur.

- The management focused on the branded nutraceuticals portfolio with new global certifications.

- The management aspired to revenue of INR 600-700cr and EBITDA of INR 130-150cr in 4-5 years.

Clariant JV

- The management remains on track to improve product mix and customer collaboration.

Finance costs

- Finance costs declined to INR 25cr (-43.6% YoY) due to debt reduction. The company targets becoming debt-free from FY28E onwards.

Capex

- Capex is expected to be minimal at INR 5-20cr in FY27E, with modular expansions using existing assets.

Outlook & Valuation: India Glycols is in a transformative and value-accretive phase, driven by an NCLT-approved demerger into three focused pure-play entities, which is expected to unlock shareholder value. The spirits business, with dominant market share in UP/Uttarakhand and captive ENA cost leadership, is aggressively expanding its premium IMFL portfolio (26% YoY growth) through partnerships with Amrut and Bacardi. The spirits business is targeting INR 500cr+ EBITDA for FY27E and a top-alco-bev position. The chemicals business, as the world's largest bio-based specialty chemicals player, is capitalizing on the global sustainability shift with innovations like bio-based amines, targeting INR 2,500cr in revenue and INR 400cr in EBITDA over 4-5 years. Ennature Bio Pharma, with its best-ever quarter and nicotine growth (2x QoQ), targets INR 130-150cr in EBITDA in 4-5 years. We estimate revenue/EBITDA/PAT CAGR of 12%/15.4%/29% over the period of FY26-29E, with EBITDA margin expanding to 16.9% (FY29E). At the CMP of INR 1,071 per share, we maintain our "BUY" rating at a TP of INR 1,639 per share, based on SOTP; an upside of 53%.

IGL FY29E based implied valuation	IGL Spirits	India Glycols	Ennature Biopharma	
FY29E EBITDA (INR cr)	701	248	49	
EV/EBITDA (x)	15.0x	5.0x	1.0x	
EV (INR cr)	10,519	1,238	49	11,806
Net Debt/(cash) (INR cr) - FY29E end				822
Market Cap (INR cr)				10,984
Share outstanding (cr)				6.7
Value per share (INR) - FY29E				**1,639**
CMP (INR)				**1,071**
Upside/Downside (%)				**53.0%**
Rating				**BUY**

Source: Company reports, Arihant Capital Research

Exhibit 8: Large liquor players are available between 25-35x EV/EBITDA, while small & medium players are available between 10-20x EV/EBITDA. IGL spirits also has Bio-fuel (~30% share) and well positioned to capture ethanol blending program. We have assigned 15x EV/EBITDA to IGL Spirits.





Source: Arihant Capital Research

Sensitivity Analysis

Exhibit 9: Changes in IGL Spirits & India Glycols multiple impact on TP

FY29E Target Price (INR)

India Glycols EV/EBITDA (x)	IGL Sprits EV/EBITDA (x)							
1,639	12.0x	13.0x	14.0x	15.0x	16.0x	17.0x	18.0x	19.0x
2.0x	1,214	1,319	1,423	1,528	1,633	1,737	1,842	1,947
3.0x	1,251	1,356	1,460	1,565	1,670	1,774	1,879	1,984
4.0x	1,288	1,393	1,497	1,602	1,707	1,811	1,916	2,021
5.0x	1,325	1,430	1,534	1,639	1,744	1,848	1,953	2,057
6.0x	1,362	1,467	1,571	1,676	1,781	1,885	1,990	2,094
7.0x	1,399	1,504	1,608	1,713	1,817	1,922	2,027	2,131
8.0x	1,436	1,541	1,645	1,750	1,854	1,959	2,064	2,168
9.0x	1,473	1,577	1,682	1,787	1,891	1,996	2,101	2,205

FY29E Target Price upside (%)

India Glycols EV/EBITDA (x)	IGL Sprits EV/EBITDA (x)							
53%	12.0x	13.0x	14.0x	15.0x	16.0x	17.0x	18.0x	19.0x
2.0x	13.4%	23.1%	32.9%	42.7%	52.5%	62.2%	72.0%	81.8%
3.0x	16.8%	26.6%	36.4%	46.1%	55.9%	65.7%	75.4%	85.2%
4.0x	20.3%	30.0%	39.8%	49.6%	59.3%	69.1%	78.9%	88.7%
5.0x	23.7%	33.5%	43.3%	53.0%	62.8%	72.6%	82.3%	92.1%
6.0x	27.2%	36.9%	46.7%	56.5%	66.2%	76.0%	85.8%	95.6%
7.0x	30.6%	40.4%	50.2%	59.9%	69.7%	79.5%	89.2%	99.0%
8.0x	34.1%	43.8%	53.6%	63.4%	73.1%	82.9%	92.7%	102.5%
9.0x	37.5%	47.3%	57.1%	66.8%	76.6%	86.4%	96.1%	105.9%

Source: Company Reports, Arihant Capital Research

Exhibit 10: Revenue and EBITDA margin change impact on PAT and EPS.

FY29E PAT (INR cr)

Revenue (INR cr)	EBITDA Margin (%)						
628	15.5%	16.0%	16.5%	17.0%	17.5%	18.0%	18.5%
5,500	520	540	561	581	602	623	643
5,700	543	564	585	607	628	649	671
5,900	566	588	610	632	654	676	698
6,100	589	612	635	658	681	703	726
6,300	612	636	660	683	707	730	754
6,500	636	660	684	709	733	757	781
6,700	659	684	709	734	759	784	809

FY29E EPS (INR)

Revenue (INR cr)	EBITDA Margin (%)						
93.7	15.5%	16.0%	16.5%	17.0%	17.5%	18.0%	18.5%
5,500	77.5	80.6	83.7	86.7	89.8	92.9	96.0
5,700	81.0	84.2	87.4	90.5	93.7	96.9	100.1
5,900	84.5	87.8	91.0	94.3	97.6	100.9	104.2
6,100	87.9	91.3	94.7	98.1	101.5	104.9	108.3
6,300	91.4	94.9	98.4	101.9	105.4	109.0	112.5
6,500	94.8	98.5	102.1	105.7	109.4	113.0	116.6
6,700	98.3	102.0	105.8	109.5	113.3	117.0	120.7

Source: Company Reports, Arihant Capital Research

Exhibit 11: Changes in EPS & PE impact on TP and EBITDA & EV/EBITDA impact on TP.

FY29E Target Price (INR)

EPS (INR)	PE (x)						
	12.0x	14.0x	16.0x	18.0x	20.0x	22.0x	24.0x
88.0	1,056	1,232	1,408	1,584	1,760	1,936	2,112
90.0	1,080	1,260	1,440	1,620	1,800	1,980	2,160
92.0	1,104	1,288	1,472	1,656	1,840	2,024	2,208
94.0	1,128	1,316	1,504	1,692	1,880	2,068	2,256
96.0	1,152	1,344	1,536	1,728	1,920	2,112	2,304
98.0	1,176	1,372	1,568	1,764	1,960	2,156	2,352
100.0	1,200	1,400	1,600	1,800	2,000	2,200	2,400

FY29E Target Price (INR)

EBITDA (INR cr)	EV/EBITDA (x)						
	6.0x	8.0x	10.0x	12.0x	14.0x	16.0x	18.0x
940	964	1,245	1,525	1,806	2,086	2,367	2,647
960	982	1,269	1,555	1,841	2,128	2,414	2,701
980	1,000	1,292	1,585	1,877	2,170	2,462	2,755
1,000	1,018	1,316	1,615	1,913	2,212	2,510	2,808
1,020	1,036	1,340	1,645	1,949	2,253	2,558	2,862
1,040	1,054	1,364	1,674	1,985	2,295	2,605	2,916
1,060	1,072	1,388	1,704	2,021	2,337	2,653	2,970

Source: Company Reports, Arihant Capital Research

Financial Statements

Income statement summary

Y/e 31 Mar (INR cr)	FY23	FY24	FY25	FY26	FY27E	FY28E	FY29E
Revenue	2,651	3,294	3,768	4,211	4,744	5,283	5,919
Net Raw Materials	1,582	2,149	2,408	2,662	2,955	3,286	3,675
Power & Fuel	417	328	362	401	466	513	569
Employee Cost	89	103	123	133	151	166	183
Other Expenses	267	311	365	367	422	456	494
EBITDA	**296**	**402**	**511**	**649**	**750**	**861**	**998**
EBITDA Margin (%)	**11.1%**	**12.2%**	**13.6%**	**15.4%**	**15.8%**	**16.3%**	**16.9%**
Depreciation	(94)	(101)	(115)	(155)	(163)	(166)	(169)
Interest expense	(100)	(121)	(164)	(167)	(101)	(71)	(60)
Other income	24	26	15	5	7	8	9
Exceptional Items	28	-	-	(1)	-	-	-
Share of profits associate & JV	11	17	46	46	50	55	62
Profit before tax	**165**	**223**	**292**	**377**	**543**	**688**	**840**
Taxes	(24)	(50)	(61)	(84)	(132)	(173)	(212)
PAT	**141**	**173**	**231**	**293**	**412**	**515**	**628**
PAT Margin (%)	**5.3%**	**5.3%**	**6.1%**	**7.0%**	**8.7%**	**9.7%**	**10.6%**
EPS (INR)	22.8	27.9	37.1	43.4	61.4	76.8	93.7

Source: Company Reports, Arihant Capital Research

Balance sheet summary

Y/e 31 Mar (INR cr)	FY23	FY24	FY25	FY26	FY27E	FY28E	FY29E
Equity capital	31	31	31	34	34	34	34
Reserves	1,870	2,020	2,225	2,899	3,266	3,724	4,283
Net worth	1,901	2,051	2,256	2,933	3,299	3,757	4,316
Minority Interest	-	-	-	-	-	-	-
Provisions	7	8	8	13	4	4	5
Debt	1,479	1,763	2,309	2,154	1,869	1,419	969
Other non-current liabilities	475	401	445	508	569	634	710
Total Liabilities	**3,863**	**4,223**	**5,018**	**5,608**	**5,741**	**5,814**	**6,000**
Fixed assets	2,690	3,171	3,736	4,445	4,339	4,281	4,221
Capital Work In Progress	125	84	98	37	38	39	39
Other Intangible assets	2	2	1	1	1	1	1
Investments	370	384	427	430	474	528	592
Other non current assets	25	31	96	110	119	132	148
Net working capital	**368**	**286**	**527**	**495**	**613**	**693**	**792**
Inventories	754	1,106	1,171	891	1,150	1,269	1,430
Sundry debtors	430	384	365	351	416	463	519
Loans & Advances	0	1	1	2	2	2	2
Other current assets	179	189	149	167	195	232	259
Sundry creditors	(752)	(1,099)	(979)	(788)	(1,007)	(1,114)	(1,240)
Other current liabilities & Prov	(244)	(295)	(179)	(127)	(142)	(158)	(178)
Cash	113	138	77	50	109	87	147
Other Financial Assets	170	127	54	39	47	53	59
Total Assets	**3,863**	**4,223**	**5,018**	**5,608**	**5,741**	**5,814**	**6,000**

Source: Company Reports, Arihant Capital Research

Du-Pont Analysis

Y/e 31 Mar	FY23	FY24	FY25	FY26	FY27E	FY28E	FY29E
Tax burden (x)	0.9	0.8	0.8	0.8	0.8	0.7	0.7
Interest burden (x)	0.8	0.7	0.7	0.8	0.9	1.0	1.0
EBIT margin (x)	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Asset turnover (x)	0.6	0.7	0.7	0.7	0.8	0.8	0.9
Financial leverage (x)	2.2	2.4	2.5	2.3	2.0	1.8	1.6
RoE (%)	**7.6%**	**8.8%**	**10.7%**	**11.3%**	**13.2%**	**14.6%**	**15.6%**

Source: Company Reports, Arihant Capital Research

Financial Statements

Cashflow summary

Y/e 31 Mar (INR cr)	FY23	FY24	FY25	FY26	FY27E	FY28E	FY29E
Profit before tax	165	223	292	377	543	688	840
Depreciation	94	101	115	155	163	166	169
Tax paid	(24)	(50)	(61)	(84)	(132)	(173)	(212)
Working capital Δ	(6)	81	(241)	32	(118)	(80)	(99)
Operating cashflow	**229**	**355**	**105**	**480**	**456**	**601**	**698**
Capital expenditure	(362)	(541)	(695)	(803)	(58)	(109)	(109)
Free cash flow	**(133)**	**(186)**	**(590)**	**(322)**	**398**	**492**	**589**
Equity raised	(8)	(0)	(1)	459	-	-	-
Investments	86	(14)	(43)	(3)	(44)	(54)	(64)
Others	12	37	8	0	(17)	(19)	(22)
Debt financing/disposal	131	284	546	(155)	(285)	(450)	(450)
Dividends paid	(23)	(23)	(25)	(75)	(45)	(57)	(69)
Other items	(53)	(74)	45	68	52	65	77
Net Δ in cash	**12**	**25**	**(60)**	**(28)**	**59**	**(22)**	**61**
Opening Cash Flow	**102**	**113**	**138**	**77**	**50**	**109**	**87**
Closing Cash Flow	**113**	**138**	**77**	**50**	**109**	**87**	**147**

Source: Company Reports, Arihant Capital Research

Ratio analysis

Y/e 31 Mar	FY23	FY24	FY25	FY26	FY27E	FY28E	FY29E
Growth matrix (%)							
Revenue growth	-7.6%	24.3%	14.4%	11.8%	12.6%	11.4%	12.0%
Op profit growth	263.3%	36.1%	26.9%	27.1%	15.5%	14.9%	15.8%
Net profit growth	-15.0%	22.7%	33.4%	26.9%	40.6%	25.1%	22.1%
Profitability ratios (%)							
OPM	11.1%	12.2%	13.6%	15.4%	15.8%	16.3%	16.9%
Net profit margin	5.7%	5.8%	5.3%	5.3%	6.1%	7.0%	8.7%
RoCE	5.9%	7.0%	7.7%	8.0%	8.8%	10.2%	12.0%
RoNW	7.6%	8.8%	10.7%	11.3%	13.2%	14.6%	15.6%
RoA	3.7%	4.1%	4.6%	5.2%	7.2%	8.9%	10.5%
Per share ratios (INR)							
EPS	22.8	27.9	37.1	43.4	61.4	76.8	93.7
Dividend per share	3.7	3.7	4.0	11.2	6.8	8.4	10.3
Cash EPS	38.0	44.2	55.9	66.9	85.7	101.6	119.0
Book value per share	307.1	331.2	364.3	437.6	492.2	560.6	644.0
Valuation ratios (x)							
P/E	46.9	38.4	28.9	24.7	17.4	13.9	11.4
P/CEPS	28.2	24.2	19.2	16.0	12.5	10.5	9.0
P/B	3.5	3.2	2.9	2.4	2.2	1.9	1.7
EV/EBITDA	27.1	20.5	17.4	14.3	11.9	9.9	8.0
Payout (%)							
Dividend payout	16.3%	13.3%	10.7%	25.7%	11.0%	11.0%	11.0%
Tax payout	14.5%	22.5%	21.0%	22.4%	24.3%	25.2%	25.2%
Liquidity ratios							
Debtor days	57	45	36	31	30	30	30
Inventory days	167	158	173	141	126	134	134
Creditor days	108	117	116	91	82	88	87
WC Days	116	86	92	82	74	77	77
Leverage ratios (x)							
Interest coverage	2.0	2.5	2.4	3.0	5.8	9.8	13.9
Net debt / equity	0.7	0.8	1.0	0.7	0.5	0.4	0.2
Net debt / op. profit	4.6	4.0	4.4	3.2	2.3	1.5	0.8

Source: Company Reports, Arihant Capital Research

Story in Charts

Exhibit 12: Potable spirits, Biofuels and recovery in chemicals will drive the growth going forward.



Exhibit 13: In-house grain based distilleries is expected to stabilize gross margin going forward.



Exhibit 14: The captive wind and solar hybrid power will reduce costs going forward.



Exhibit 15: Growth in EBITDA & PAT levels.



Exhibit 16: Working capital days to be improve



Exhibit 17: Cash flows to be improve



Source: Company Reports, Arihant Capital Research

Story in Charts

Exhibit 18: Return ratios to be improve.



Exhibit 19: Working capital is expected to be below 15% in terms of sales going forward.



Exhibit 20: Cash conversion cycle is expected to maintain going forward.



Exhibit 21: The company is aggressively repaying the debt.



Exhibit 22: Ethanol blending, Potable Sprits and recovery in BSPC and will drive growth.



Exhibit 23: Segment wise mix



Source: Company Reports, Arihant Capital Research

Arihant Research Desk

Email: instresearch@arihantcapital.com

Tel. : 022-42254800

Head Office	Registered Office
#1011, Solitaire Corporate Park	
Building No. 10, 1st Floor	6 Lad Colony,
Andheri Ghatkopar Link Road	Y.N. Road,
Chakala, Andheri (E)	Indore - 452003, (M.P.)
Mumbai – 400093	Tel: (91-731) 4217100/101
Tel: (91-22) 42254800	CIN: L66120MP1992PLC007182

Stock Rating Scale	Absolute Return
BUY	>20%
ACCUMULATE	12% to 20%
HOLD	5% to 12%
NEUTRAL	-5% to 5%
REDUCE	-5% to -12%
SELL	<-12%

Research Analyst Registration No.	Contact	Website	Email Id
INH000002764	SMS: 'Arihant' to 56677	www.arihantcapital.com	instresearch@arihantcapital.com

Arihant Capital Markets Ltd.
1011, Solitaire Corporate park, Building No. 10, 1st Floor,
Andheri Ghatkopar Link Road, Chakala, Andheri (E)
Tel. 022-42254800

Disclaimer: This disclosure statement is provided in compliance with the SEBI Research Analyst Regulations, 2014. Arihant Capital Markets Limited (ACML) is a registered stockbroker, merchant banker, and research analyst under SEBI, and is also a Point of Presence with the Pension Fund Regulatory and Development Authority (PFRDA). ACML is registered with SEBI with Research Analyst Registration Number INH000002764, Stock Broker Registration Number INZ000180939, and is a Trading Member with NSE, BSE, MCX, NCDEX, and a Depository Participant with CDSL and NSDL.

ACML and its associates may have business relationships, including investment banking, with companies covered by its Investment Research Department. The analysts of ACML, and their associates, are prohibited from holding a financial interest in securities or derivatives of companies they cover, though they may hold stock in the companies they analyze. The recommendations provided by ACML's research team are based on technical and derivative analysis and may differ from fundamental research reports.

ACML confirms that neither it nor its associates have a financial interest or material conflict concerning the companies covered in the research report at the time of publication. Furthermore, ACML, its analysts, and their relatives have no ownership greater than 1% in the subject companies as of the month prior to publication. ACML guarantees that the compensation for its research analysts is not influenced by specific securities or transactions.

ACML affirms that neither the analyst nor the company has served as an officer, director, employee, or engaged in market-making activities for any of the subject companies. Additionally, the research report does not reflect any conflict of interest and is not influenced by specific recommendations made. Neither ACML nor its analysts have received compensation for investment banking or brokerage services from the subject companies in the last 12 months.

The views expressed in this report are those of the analysts and are independent of the proprietary trading desk of ACML, which operates separately to maintain an unbiased stance. Analysts comply with SEBI Regulations when offering recommendations or opinions through public media. The report is intended for informational purposes only and is not an offer or solicitation for the purchase or sale of securities.

This report, which is confidential, may not be reproduced or shared without written consent from ACML. It is based on publicly available data believed to be reliable but has not been independently verified, and no guarantees are made about its accuracy. All opinions and information contained in the report are subject to change without notice.
ACML disclaims liability for any losses resulting from reliance on this report. The report does not constitute an offer to buy or sell securities, and ACML is not responsible for the risks involved in investments. ACML and its affiliates may have positions in the securities discussed or hold other financial interests in them.

The distribution of this report in certain jurisdictions may be restricted by law, and the report is not intended for distribution where it would violate local laws. Investors are advised to consider their financial position, risk tolerance, and investment objectives before engaging in transactions, particularly in high-risk financial products such as derivatives.

ACML reserves the right to modify this disclosure statement without prior notice. The report has been prepared using publicly available information and internally developed data, though ACML does not guarantee its completeness or accuracy. Historical price data for securities can be accessed via official exchanges like NSE or BSE.
ACML and its affiliates may conduct proprietary transactions or investment banking services for the companies mentioned in this report. In compliance with SEBI regulations, ACML maintains comprehensive records of research reports, recommendations, and the rationale for those recommendations, which are preserved for at least five years. An annual compliance audit is conducted by a member of the ICAI or ICSI to ensure adherence to applicable regulations. This report is issued in accordance with applicable SEBI regulations and does not guarantee future performance or returns.

Arihant Capital Markets Ltd.
1011, Solitaire Corporate park, Building No. 10, 1st Floor,
Andheri Ghatkopar Link Road, Chakala, Andheri (E)
Tel. 022-42254800

Abhishek Jain
Head of Research
Abhishek.jain@arihantcapital.com

Abhishek Chhajed Jain
Digitally signed by Abhishek Chhajed Jain
Date: 2026.08.18 15:43:52 +05'30'